See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $95.5B | 8.1x | 23.1x | |
| $9.5B | 3.1x | 11.1x | |
| $4.3B | 12.1x | 28.3x | |
| $4.1B | 120.6x | -7.5x | |
| $3.8B | 10.7x | 29.0x | |
| $2.7B | 4.5x | 36.3x | |
| $2.7B | 738.9x | -159.6x | |
| $1.9B | 65.5x | -32.1x | |
| $1.7B | 6.3x | 25.1x | |
| $1.4B | n/a | n/a | |
| $1.3B | 26.0x | -3.0x | |
| $1.2B | 1396.0x | -47.7x | |
| $960M | 15.9x | -2.1x | |
| $926M | 2.5x | 11.2x | |
| $808M | 3.8x | 32.0x | |
| $712M | 1.5x | 16.9x | |
| $528M | 11.3x | 91.6x | |
| $520M | n/a | n/a | |
| $484M | 16.8x | -3.0x | |
| $456M | 14.1x | 28.1x | |
| $362M | 305.3x | n/a | |
| $275M | 31.0x | -8.4x | |
| $221M | 85.9x | n/a | |
| $200M | n/a | n/a | |
| $185M | 7.1x | 15.2x | |
| $169M | 25.1x | -42.0x | |
| $157M | 21.5x | -1.8x | |
| $142M | 2.6x | 42.1x | |
| $127M | n/a | n/a | |
| $104M | 350.4x | -0.5x | |
| $96.5M | 0.9x | 16.7x | |
| $81.7M | n/a | n/a | |
| $70.7M | n/a | -5.4x | |
| $68.9M | 0.3x | n/a | |
| $68.3M | 2.5x | -5.1x | |
| $63.4M | 205.2x | -0.4x | |
| $61.1M | 685.5x | n/a | |
| $41.9M | n/a | n/a | |
| $27.8M | n/a | n/a | |
| $26.3M | 7.4x | -3.6x | |
| $24.4M | 3.8x | n/a | |
| $23.9M | n/a | n/a | |
| $15.7M | n/a | n/a | |
| $6.4M | 4.1x | n/a | |
| -$7.4M | n/a | n/a | |
| -$110M | -1.2x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine